iTRAQ-based high-throughput proteomics analysis reveals alterations of plasma proteins in patients infected with human bocavirus.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
07
2019
accepted:
31
10
2019
entrez:
22
11
2019
pubmed:
22
11
2019
medline:
24
3
2020
Statut:
epublish
Résumé
Human bocavirus (HBoV) is a member of the genus Bocavirus, family Parvoviridae, and subfamily Parvovirus and was first identified in nasopharyngeal aspirates of Swedish children with acute respiratory tract infection (ARTI) in 2005. It is the causative agent of nasopharyngeal aspirate disease and death in children. The HboV genomic structure is a linear single-stranded DNA (ssDNA). Its clinical pathogenic characteristics have been extensively studied, however, at present the molecular mechanism underlying the pathogenesis of HBoV infection is not completely clear. In this study, a total of 293 differentially expressed proteins (DEPs) between ARTI cases and healthy plasma samples were characterized using isobaric tags for relative and absolute quantitation (iTRAQ)-coupled bioinformatics analysis, among which 148 were up-regulated and 135 were down-regulated. Gene Ontology (GO) and Cluster of Orthologous Groups of proteins (COG) annotated an enrichment of DEPs in complement activation and biological processes like immunity, inflammation, signal transduction, substance synthesis, and metabolism. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis enriched DEPs mainly in the Wnt signaling pathway (ko04310), PPAR signaling pathway (ko03320), intestinal immune network for IgA production (ko04672), complement and coagulation cascades (ko04610), Toll-like receptor signaling pathway (ko04620) and B cell receptor signaling pathway (ko04662). Further, expression levels of three candidate proteins (upregulated PPP2R1A and CUL1, and downregulated CETP) were validated using western blotting. Our investigation is the first analysis of the proteomic profile of HBoV-infected ARTI cases using the iTRAQ approach, providing a foundation for a better molecular understanding of the pathogenesis of ARTI in children.
Identifiants
pubmed: 31751365
doi: 10.1371/journal.pone.0225261
pii: PONE-D-19-15795
pmc: PMC6872134
doi:
Substances chimiques
Blood Proteins
0
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0225261Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2012 Jun 9;379(9832):2151-61
pubmed: 22579125
Mol Aspects Med. 2009 Aug;30(4):191-296
pubmed: 19371762
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12891-6
pubmed: 16118271
PLoS One. 2018 Jan 11;13(1):e0191010
pubmed: 29324866
J Virol. 2011 Mar;85(6):2869-77
pubmed: 21209107
Virology. 2009 Feb 20;384(2):317-23
pubmed: 19013629
Arch Virol. 2009;154(12):1923-7
pubmed: 19862470
Proteomics. 2015 Jun;15(11):1819-28
pubmed: 25604190
Virology. 2009 Sep 1;391(2):325-33
pubmed: 19628238
Proteomics. 2016 May;16(10):1499-514
pubmed: 26989863
Trends Microbiol. 2015 Dec;23(12):789-798
pubmed: 26439298
Anim Genet. 2012 Jun;43(3):328-32
pubmed: 22486506
J Chem Neuroanat. 2004 Sep;28(1-2):51-65
pubmed: 15363491
Rev Med Virol. 2012 Jan;22(1):46-64
pubmed: 22038931
Antiviral Res. 2010 Aug;87(2):187-94
pubmed: 20452380
Clin Infect Dis. 2007 Apr 1;44(7):904-10
pubmed: 17342639
J Infect Dis. 2009 Jan 15;199(2):196-200
pubmed: 19072716
Sci Rep. 2017 Apr 04;7:45922
pubmed: 28374783
J Proteomics. 2016 Jan 1;130:65-75
pubmed: 26361011
Viruses. 2016 May 12;8(5):
pubmed: 27187445
J Virol. 2012 Nov;86(21):11745-53
pubmed: 22915798
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17039-44
pubmed: 15572443
J Virol. 1986 Dec;60(3):1085-97
pubmed: 3783814
PLoS One. 2012;7(6):e39644
pubmed: 22761854
World J Gastroenterol. 2016 Oct 21;22(39):8684-8697
pubmed: 27818586
Int J Biol Markers. 2017 May 4;32(2):e202-e209
pubmed: 28315506
Proteomics. 2014 Aug;14(16):1933-42
pubmed: 24888898
J Proteome Res. 2013 Feb 1;12(2):594-604
pubmed: 23270375
Tumour Biol. 2016 Sep;37(9):12823-12831
pubmed: 27449035
Oncotarget. 2016 Apr 12;7(15):20312-23
pubmed: 26967385
Curr Opin Virol. 2012 Oct;2(5):606-13
pubmed: 23025912
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
Int Immunol. 2009 Apr;21(4):317-37
pubmed: 19246554
J Infect Dis. 2010 Jun 1;201(11):1633-43
pubmed: 20415538
J Virol. 2014 Sep 1;88(17):9877-92
pubmed: 24942569
Mol Cell Proteomics. 2004 Dec;3(12):1154-69
pubmed: 15385600
BMC Res Notes. 2018 Jul 20;11(1):495
pubmed: 30029615
J Clin Virol. 2008 Jan;41(1):29-33
pubmed: 18055252
Croat Med J. 2013 Apr;54(2):122-34
pubmed: 23630140
PPAR Res. 2017;2017:1830626
pubmed: 28529521
Expert Rev Proteomics. 2011 Apr;8(2):153-5
pubmed: 21501008
J Immunol. 2012 Jul 1;189(1):279-86
pubmed: 22661095
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Parasitology. 2014 Aug;141(9):1192-202
pubmed: 25004926
Biochem J. 1999 Dec 1;344 Pt 2:281-92
pubmed: 10567207
Adv Exp Med Biol. 2010;694:38-46
pubmed: 20886755
J Infect Dis. 2006 Nov 1;194(9):1276-82
pubmed: 17041854
J Virol. 2015 Jun;89(12):6352-63
pubmed: 25855731
Annu Rev Biochem. 2009;78:477-513
pubmed: 19489727
PLoS Pathog. 2009 Apr;5(4):e1000391
pubmed: 19381259
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):238-43
pubmed: 25535343